Published by Josh White on 12th October 2023
(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in-class 'Bi-Cygni' antibody drug conjugate (ADC) developed for the potential treatment of acute myeloid leukaemia (AML).
URL: http://www.digitallook.com/dl/news/story/33833467/...